Company: IMNN
Filing Date: 2025-05-12
Form Type: 10-Q
Source: 0001641172-25-009572
Chunk: 93

Company: Imunon, Inc.
Filing Date: 2025-05-12
Form: 10-Q
Item: Part I, Item 8
Chunk 93
---
 to obtain additional funds sooner or in greater amounts than it currently anticipates.
Potential sources of financing include strategic relationships, public or private sales of the Company’s shares or debt and other
sources. If the Company raises funds by selling additional shares of common stock or other securities convertible into common stock, the
ownership interest of existing stockholders may be diluted.

The actual amount of funds the Company will need to
operate is subject to many factors, some of which are beyond the Company’s control. These factors include the progress of research
activities; the number and scope of research programs; the progress of preclinical and clinical development activities; the progress of
the development efforts of parties with whom the Company has entered into research and development agreements; the costs associated with
additional clinical trials of drug candidates; the ability to maintain current research and development licensing arrangements and to
establish new research and development and licensing arrangements; the ability to achieve milestones under licensing arrangements; the
costs involved in prosecuting and enforcing patent claims and other intellectual property rights; and the costs and timing of regulatory
approvals.

    8

A fundamental component of the ability
to continue as a going concern is the Company’s ability to raise capital as required, as to which no assurances can be provided.
To address the additional funding requirements of the Company, management has undertaken the following initiatives:

    ●
    it has assessed its current expenditures and will reduce spending where necessary;

    ●
    it
will pursue additional capital funding in the public and private markets through equity sales and/or debt facilities;

    ●
    it
will pursue possible partnerships and collaborations; and

    ●
    it
will pursue potential out licensing for its drug candidates.

 The Company’s ability to
continue as a going concern will depend on its ability to raise additional capital, attain further operating efficiencies, reduce
expenditures, and, ultimately, to generate revenue. There are no assurances that these future funding and operating efforts will be
successful. If management is unsuccessful in these efforts, the Company’s current capital is not expected to be sufficient to fund our
operations for the next twelve months.

Management’s
plan includes private or public equity financings, collaborations, or other strategic transactions such as raising funds from outside
investors via its ATM program and other potential funding sources. The Company may not be able to obtain funding on acceptable terms,
or at all. The terms of any financing may adversely affect the holdings or the rights of the Company’s stockholders. The Company’s
ability to